0	7	Effects	Effect	NNPS
8	10	of	of	IN
11	24	prostaglandin	prostaglandin	NN
25	27	E2	e2	NN
28	30	on	on	IN
31	39	Th0-type	th0-type	JJ
40	45	human	human	JJ
46	47	T	t	NN
48	52	cell	cell	NN
53	59	clones	clone	NNS
59	60	:	:	:
61	71	modulation	modulation	NN
72	74	of	of	IN
75	84	functions	function	NNS
85	87	of	of	IN
88	95	nuclear	nuclear	JJ
96	104	proteins	protein	NNS
105	113	involved	involve	VBN
114	116	in	in	IN
117	125	cytokine	cytokine	NN
126	136	production	production	NN
136	137	.	.	.

139	142	The	the	DT
143	150	effects	effect	NNS
151	153	of	of	IN
154	167	prostaglandin	prostaglandin	NN
168	170	E2	e2	NN
171	172	(	(	(
172	176	PGE2	pge2	NN
176	177	)	)	)
178	180	on	on	IN
181	189	cytokine	cytokine	NN
190	200	production	production	NN
201	204	and	and	CC
205	218	proliferation	proliferation	NN
219	221	of	of	IN
222	225	the	the	DT
226	230	CD4+	cd4+	JJ
231	236	human	human	JJ
237	243	helper	helper	NN
244	245	T	t	NN
246	250	cell	cell	NN
251	256	clone	clone	NN
257	263	SP-B21	sp-b21	NN
264	268	were	be	VBD
269	281	investigated	investigate	VBN
281	282	.	.	.

283	285	In	in	IN
286	291	cells	cell	NNS
292	302	stimulated	stimulate	VBN
303	307	with	with	IN
308	316	anti-CD3	anti-cd3	JJ
317	320	mAb	mab	NN
320	321	,	,	,
322	326	PGE2	PGE2	NNP
327	336	inhibited	inhibit	VBD
337	341	cell	cell	NN
342	355	proliferation	proliferation	NN
356	359	and	and	CC
360	363	the	the	DT
364	374	production	production	NN
375	377	of	of	IN
378	381	all	all	PDT
382	385	the	the	DT
386	395	cytokines	cytokine	NNS
396	404	examined	examine	VBN
404	405	.	.	.

406	414	Addition	addition	NN
415	417	of	of	IN
418	423	rIL-2	ril-2	NN
424	429	fully	fully	RB
430	438	restored	restore	VBD
439	442	the	the	DT
443	456	proliferative	proliferative	JJ
457	465	response	response	NN
466	469	and	and	CC
470	479	partially	partially	RB
480	488	restored	restore	VBD
489	492	the	the	DT
493	503	production	production	NN
504	506	of	of	IN
507	511	IL-4	il-4	NN
512	515	and	and	CC
516	520	IL-5	il-5	NN
520	521	,	,	,
522	525	but	but	CC
526	529	not	not	RB
530	534	that	that	DT
535	537	of	of	IN
538	543	other	other	JJ
544	553	cytokines	cytokine	NNS
553	554	.	.	.

555	557	In	in	IN
558	566	contrast	contrast	NN
566	567	,	,	,
568	570	in	in	IN
571	576	cells	cell	NNS
577	587	stimulated	stimulate	VBN
588	592	with	with	IN
593	600	phorbol	phorbol	NN
601	610	myristate	myristate	NN
611	618	acetate	acetate	NN
619	620	(	(	(
620	631	PMA)/A23187	PMA)/A23187	NNP
631	632	,	,	,
633	637	PGE2	PGE2	NNP
638	646	enhanced	enhance	VBD
647	650	the	the	DT
651	661	production	production	NN
662	664	of	of	IN
665	669	IL-4	il-4	NN
670	673	and	and	CC
674	678	IL-5	il-5	NN
678	679	,	,	,
680	683	and	and	CC
684	688	only	only	RB
689	698	partially	partially	RB
699	708	inhibited	inhibit	VBD
709	712	the	the	DT
713	723	production	production	NN
724	726	of	of	IN
727	732	other	other	JJ
733	742	cytokines	cytokine	NNS
742	743	.	.	.

744	753	Therefore	therefore	RB
753	754	,	,	,
755	758	the	the	DT
759	766	effects	effect	NNS
767	769	of	of	IN
770	774	PGE2	pge2	NN
775	779	vary	vary	VBP
780	789	depending	depend	VBG
790	792	on	on	IN
793	796	the	the	DT
797	801	mode	mode	NN
802	804	of	of	IN
805	806	T	t	NN
807	811	cell	cell	NN
812	822	activation	activation	NN
822	823	,	,	,
824	827	and	and	CC
828	831	the	the	DT
832	836	IL-4	il-4	NN
837	840	and	and	CC
841	845	IL-5	il-5	NN
846	849	are	be	VBP
850	859	regulated	regulate	VBN
860	871	differently	differently	RB
872	876	from	from	IN
877	882	other	other	JJ
883	892	cytokines	cytokine	NNS
892	893	.	.	.

894	896	In	in	IN
897	898	a	a	DT
899	907	mobility	mobility	NN
908	913	shift	shift	NN
914	919	assay	assay	NN
919	920	,	,	,
921	925	only	only	RB
926	929	the	the	DT
930	938	NF-kappa	NF-kappa	NNP
939	940	B	B	NNP
941	942	(	(	(
942	949	p50/p50	p50/p50	NN
949	950	)	)	)
951	960	homodimer	homodimer	NN
961	964	was	be	VBD
965	973	observed	observe	VBN
974	976	in	in	IN
977	978	a	a	DT
979	986	complex	complex	NN
987	993	formed	form	VBN
994	998	with	with	IN
999	1002	the	the	DT
1003	1008	kappa	kappa	NN
1009	1010	B	B	NNP
1011	1019	sequence	sequence	NN
1020	1022	in	in	IN
1023	1035	unstimulated	unstimulated	JJ
1036	1042	SP-B21	sp-b21	NN
1043	1048	cells	cell	NNS
1048	1049	.	.	.

1050	1054	When	when	WRB
1055	1060	cells	cell	NNS
1061	1065	were	be	VBD
1066	1076	stimulated	stimulate	VBN
1077	1081	with	with	IN
1082	1090	anti-CD3	anti-cd3	JJ
1091	1094	mAb	mab	NN
1095	1097	or	or	CC
1098	1108	PMA/A23187	PMA/A23187	NNP
1108	1109	,	,	,
1110	1111	a	a	DT
1112	1119	complex	complex	JJ
1120	1129	formation	formation	NN
1130	1132	of	of	IN
1133	1141	NF-kappa	NF-kappa	NNP
1142	1143	B	B	NNP
1144	1145	(	(	(
1145	1152	p50/p65	p50/p65	NN
1152	1153	)	)	)
1154	1165	heterodimer	heterodimer	NN
1166	1170	with	with	IN
1171	1174	the	the	DT
1175	1180	kappa	kappa	NN
1181	1182	B	B	NNP
1183	1191	sequence	sequence	NN
1192	1195	was	be	VBD
1196	1203	induced	induce	VBN
1203	1204	.	.	.

1205	1218	Interestingly	interestingly	RB
1218	1219	,	,	,
1220	1224	PGE2	pge2	NN
1225	1227	or	or	CC
1228	1238	di-butyryl	di-butyryl	NN
1239	1240	(	(	(
1240	1248	Bt2)cAMP	Bt2)cAMP	NNP
1249	1258	abolished	abolish	VBD
1259	1262	the	the	DT
1263	1270	binding	binding	NN
1271	1273	of	of	IN
1274	1282	NF-kappa	NF-kappa	NNP
1283	1284	B	B	NNP
1285	1286	(	(	(
1286	1293	p50/p65	p50/p65	NN
1293	1294	)	)	)
1295	1306	heterodimer	heterodimer	NN
1307	1309	to	to	TO
1310	1313	the	the	DT
1314	1319	kappa	kappa	NN
1320	1321	B	B	NNP
1322	1330	sequence	sequence	NN
1331	1333	in	in	IN
1334	1339	cells	cell	NNS
1340	1350	stimulated	stimulate	VBN
1351	1355	with	with	IN
1356	1364	anti-CD3	anti-cd3	JJ
1365	1368	mAb	mab	NN
1369	1372	but	but	CC
1373	1376	not	not	RB
1377	1381	with	with	IN
1382	1392	PMA/A23187	PMA/A23187	NNP
1392	1393	.	.	.

1394	1397	Our	our	PRP$
1398	1405	results	result	NNS
1406	1413	suggest	suggest	VBP
1414	1418	that	that	IN
1419	1422	the	the	DT
1423	1429	target	target	NN
1430	1432	of	of	IN
1433	1437	PGE2	pge2	NN
1438	1444	action	action	NN
1445	1447	is	be	VBZ
1448	1449	a	a	DT
1450	1459	component	component	NN
1460	1462	in	in	IN
1463	1466	the	the	DT
1467	1473	signal	signal	NN
1474	1486	transduction	transduction	NN
1487	1494	pathway	pathway	NN
1495	1502	leading	lead	VBG
1503	1505	to	to	TO
1506	1509	the	the	DT
1510	1520	activation	activation	NN
1521	1523	of	of	IN
1524	1531	protein	protein	NN
1532	1538	kinase	kinase	NNP
1539	1540	C	C	NNP
1540	1541	.	.	.

1542	1549	However	however	RB
1549	1550	,	,	,
1551	1554	the	the	DT
1555	1565	inhibition	inhibition	NN
1566	1568	of	of	IN
1569	1572	the	the	DT
1573	1574	T	t	NN
1575	1579	cell	cell	NN
1580	1590	activation	activation	NN
1591	1598	signals	signal	NNS
1599	1601	by	by	IN
1602	1606	PGE2	pge2	NN
1607	1609	is	be	VBZ
1610	1619	selective	selective	JJ
1619	1620	.	.	.

1621	1625	PGE2	PGE2	NNP
1626	1634	enhanced	enhance	VBD
1635	1638	the	the	DT
1639	1646	complex	complex	NN
1647	1656	formation	formation	NN
1657	1661	with	with	IN
1662	1667	NF-AT	NF-AT	NNP
1667	1668	,	,	,
1669	1673	AP-1	ap-1	NN
1674	1677	and	and	CC
1678	1682	CLE0	cle0	NN
1683	1692	sequences	sequence	NNS
1693	1697	when	when	WRB
1698	1701	the	the	DT
1702	1707	cells	cell	NNS
1708	1712	were	be	VBD
1713	1722	activated	activate	VBN
1723	1725	by	by	IN
1726	1732	either	either	CC
1733	1741	anti-CD3	anti-cd3	JJ
1742	1745	mAb	mab	NN
1746	1748	or	or	CC
1749	1759	PMA/A23187	pma/a23187	NN
1760	1771	stimulation	stimulation	NN
1771	1772	.	.	.

1773	1775	It	it	PRP
1776	1781	seems	seem	VBZ
1782	1791	therefore	therefore	RB
1792	1796	that	that	IN
1797	1801	PGE2	pge2	NN
1801	1802	,	,	,
1803	1805	by	by	IN
1806	1815	elevating	elevate	VBG
1816	1820	cAMP	camp	NN
1821	1827	levels	level	NNS
1827	1828	,	,	,
1829	1839	interferes	interfere	VBZ
1840	1844	with	with	IN
1845	1848	the	the	DT
1849	1859	activation	activation	NN
1860	1867	pathway	pathway	NN
1868	1871	for	for	IN
1872	1880	NF-kappa	NF-kappa	NNP
1881	1882	B	B	NNP
1883	1886	but	but	CC
1887	1890	not	not	RB
1891	1894	for	for	IN
1895	1900	NF-AT	NF-AT	NNP
1900	1901	,	,	,
1902	1906	AP-1	ap-1	NN
1907	1909	or	or	CC
1910	1914	CLE0	cle0	NN
1915	1922	binding	binding	NN
1923	1930	protein	protein	NN
1930	1931	.	.	.